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Association of leukocyte mitochondrial DNA
content with glioma risk: evidence from a
Chinese case–control study
Jie Zhang1†, Deyang Li2†, Falin Qu2, Yibing Chen2, Gang Li3, Hequn Jiang1, Xiaojun Huang2, Hushan Yang4
and Jinliang Xing2*

Abstract
Background: Increasing evidence suggests that alterations in mitochondrial DNA (mtDNA) content may be
implicated in the tumorigenesis of several malignancies. However, the association between mtDNA content in
peripheral blood lymphocytes (PBLs) and glioma risk has not been investigated.
Methods: Real-time PCR was used to examine the mtDNA content in PBLs of 414 glioma patients and 414
matched controls in a hospital-based case–control study. The association between mtDNA content and glioma risk
was evaluated using an unconditional multivariate logistic regression model.
Results: We found that glioma patients exhibited a significantly higher median mtDNA content than healthy
controls (0.99 vs. 0.71, P < 0.001). Unconditional multivariate logistic regression analysis adjusting for age, gender,
smoking status, and family cancer history showed that there was an S-shaped association between mtDNA content
and glioma risk. Higher mtDNA content was significantly associated with an elevated risk of glioma. Compared with
the first quartile, the odds ratio (95% confidence interval) for subjects in the second, third, and fourth quartiles of
mtDNA content were 0.90 (0.52-1.53), 3.38 (2.15-5.31), and 5.81 (3.74-9.03), respectively (P for nonlinearity = 0.009).
Stratified analysis showed that the association between mtDNA content and glioma risk was not modulated by
major host characteristics.
Conclusions: Our findings demonstrate for the first time that a higher mtDNA content in PBLs is associated with
an elevated risk of glioma, which warrants further investigation in larger populations.
Keywords: Case–control study, Mitochondrial DNA content, Peripheral blood leukocyte, Real-time PCR, Glioma risk

Background
Glioma is the most common primary brain tumor in
both adults and children [1]. It is histologically classified
into four grades (grades I-IV) according to the World
Health Organization (WHO) guidelines and about 70%
of glioma is malignant (grade III/IV). The key features of
malignant glioma include local invasive growth and
strong angiogenesis. Despite many advances in surgical
and medical therapies in recent years, the clinical outcome of this disease is still dismal under the best
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available treatment regimen. The median overall survival
is 12 ~ 14 months in glioblastoma patients and 2 ~
5 years in anaplastic astrocytoma patients. Currently,
brain-imaging technology such as magnetic resonance
imaging has proven to be the most effective method of
diagnosing glioma. However, the use of brain imaging is
dramatically limited in early preventive screening of glioma due to its high cost and low sensitivity for early
stage glioma. Although numerous genetic and molecular
research projects have been focused on the development
of glioma, the pathogenesis of glioma is still poorly
understood. Hence, there is a pressing need to develop
novel specific susceptible biomarkers for the prediction
of glioma risk and early diagnosis.

© 2014 Zhang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Mitochondria play pivotal roles in cellular energy production, free radical generation, apoptosis, and are the
major intracellular source and primary target of reactive
oxygen species (ROS) [2]. Human mitochondrial DNA
(mtDNA) is a circular double-stranded DNA molecule
with a length of 16569 bp. Each mitochondrion contains
2–10 mtDNA molecules. The copy number of mtDNA
generally remains within a relatively stable range in order
to maintain the cell’s energy demands and preserve its
normal physiological functions. However, mtDNA copy
number may change from 102 to 104 per cell depending
on the cell energy demands, and also vary in different cell
types and tissue origins [3]. Compared with nuclear DNA,
mtDNA lacks protective histones and appears to have less
efficient repair mechanisms. Therefore, it is particularly
susceptible to damage caused by ROS and other genotoxic
agents [4]. Previous studies have indicated a potential involvement of both mtDNA mutations and alterations of
mtDNA content (increased or decreased) in the tumorigenesis of many malignancies [5-8]. For example, mtDNA
content in patient tissues has been found to be increased
in cancers of head and neck, ovary and esophagus [5,9,10],
and decreased in hepatocellular carcinoma (HCC), advanced gastric cancer, osteosarcoma, breast cancer and
renal cell carcinoma (RCC) [8,11-14]. In addition, several
studies have demonstrated that the alterations of mtDNA
content in peripheral blood lymphocytes (PBLs) can be
used as a surrogate of constitutive genetic background to
predict the risk of cancers such as RCC, breast cancer,
lung cancer, non-Hodgkin lymphoma (NHL), and colorectal cancer (CRC) [15-19]. However, to date, the association
between mtDNA content in PBLs and glioma susceptibility has not been determined.
In the present study, we conducted a case–control epidemiological analysis to examine the association between
PBL mtDNA content and glioma risk. We measured the
mtDNA content in PBLs from glioma patients and
matched healthy controls using quantitative real-time
PCR, and evaluated their associations with glioma risk
using multivariate logistic regression model. To the best
of our knowledge, this is the first epidemiological study to
investigate the role of mtDNA content in glioma etiology.

Methods
Study population

In this case–control study, patients with histologically
confirmed primary glioma were consecutively recruited
from the Department of Neurosurgery in Tangdu Hospital affiliated with the Fourth Military Medical University, Xi’an, Shaanxi, China, between February 2010 and
June 2012. Among a total of 495 eligible patients, 414
were successfully interviewed and donated biological
specimens with a participation rate of 83.6% during the
study period. All cases had no previous cancer history
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and no prior treatment at enrollment. There was no age,
sex, or disease stage restriction for case recruitment. The
414 healthy controls without previous cancer history were
recruited from individuals who visited the Tangdu Hospital for physical examination, during the same time
period as the case enrollment. The response rate of controls was 73.2%. The controls were frequency-matched to
the cases on age (±3 years), sex and residential areas. All
participants were Han Chinese.
Epidemiological data

After signed informed consent was obtained from each
individual, all participants were interviewed by trained
staff interviewers to collect demographic and personal
data using a standardized epidemiological questionnaire,
including age, gender, smoking history, family history of
cancer, ionizing irradiation (IR) exposure history, and
other potential confounders. Clinical information on
pathological types was collected through pathological
reports. Individuals who smoked less than 100 cigarettes
during their lifetime were categorized as never-smokers.
Individuals who smoked more than 100 cigarettes during
their lifetime were categorized as ever-smokers. The
number of pack-years was calculated as the average number of cigarettes smoked per day divided by 20 cigarettes
and then multiplied by smoking years. All information
exhibited high consistency except IR exposure history,
which might stem from inaccurate understanding of IR
exposure questionnaires. Therefore, data on IR exposure
were not used for the further analyses in this study.
Before any treatment, 5 mL of venous blood from each
participant was drawn into coded sodium citrate-coated
tubes and centrifuged at 4°C under 1200 × g within
30 min. Genomic DNA was extracted from PBLs using
the E.Z.N.A. Blood DNA Midi Kit (Omega Bio-Tek,
Norcross, GA) and stored at −80°C until PCR examination. Laboratory personnel were blinded to the case–
control status of the samples. This study was approved
by the Ethical Committee of the Fourth Military Medical
University and performed in accordance with the ethical
standards of the Helsinki Declaration.
Determination of mtDNA content by quantitative
real-time PCR

Relative mtDNA content was measured by a quantitative
real-time PCR-based method as previously described,
with the same primers that were used for the mitochondrial ND1 gene (ND-R and ND-F) and the single-copy
nuclear gene human globulin (HGB-1and HGB-2) [17].
In short, two pairs of primers were used in the two steps
of relative quantification for mtDNA copy number. In
the first step, the ratio of mtDNA copy number to HGB
copy number was calculated for each sample from
standard curves. In the second step, the ratio for each
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sample was normalized to a calibrator DNA in order to
standardize between different runs, and then defined as
the measurement of relative mtDNA content.
The PCR reaction system (20 μL) consisted of 1 × SYBR
green mastermix (TaKaRa, Dalian, China), 10 nM ND1-R
(or HGB-1) primer, 10 nM ND1-F (or HGB-2) primer,
and 8 ng of genomic DNA. The thermal cycling conditions for both primer pairs were 95°C for 30 sec, followed
by 35 cycles of 94°C for 30 sec, 58°C for 30 sec, and 72°C
for 50 sec with signal acquisition. The PCRs were always
performed on separate 96-well plates, with the same samples in the same well positions. All samples were assayed
in duplicate using the Mx3005P QPCR System (Agilent,
Santa Clara, CA). In each run, negative and positive controls, a calibrator DNA, and a standard curve were included. For each standard curve, one reference DNA
sample (the same DNA sample for all runs) was diluted
with a 3-fold increment per dilution to produce a 5-point
standard curve between 0.593 ng and 48 ng DNA in each
reaction. The R2 for each standard curve was ≥ 0.99, with
acceptable standard deviations set at 0.25 (for the Ct
values). Otherwise, the test was repeated.
Statistical analysis

All statistical analyses were performed using the SPSS Statistics 19.0 software (IBM). Normally distributed data were
expressed as Mean ± SD, while abnormally distributed data
were expressed as median with a bracketed range. Pearson
χ2 test was used to examine differences in the distribution
of categorical variables including age, sex, smoking status,
and family history of cancer among cases and controls. For
the normally distributed continuous variables (pack-years
of smoking), Student’s t test was used to test the differences
between cases and controls. The significance of differences
between cases and controls for abnormally distributed continuous variables (mtDNA content) was determined by
Mann–Whitney U test. The mtDNA content was also analyzed as a categorical variable by grouping it based on the
median, tertile or quartile values in the controls. The association between glioma risk and mtDNA content was estimated using odds ratio (OR) and 95% confidential interval
(CI) in unconditional multivariate logistic regression analysis after adjustment by age, sex, smoking status, and family history of cancer, where appropriate. A restricted cubic
spline was plotted to evaluate the shape of the association
as previously described [20]. Likelihood ratio tests were
used to evaluate linear, effect, and overall effects of mtDNA
content on glioma risk. All P values reported were twosided, and P < 0.05 was considered to be statistically
significant.

Results
A total of 414 glioma patients and 414 matched healthy
controls were included in this study. Table 1 summarized
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the characteristics of each type of distribution. The glioma cases and healthy controls were well-matched on
sex (P = 1.00) and age (P = 0.491). There was no statistically significant difference between cases and controls
in terms of family cancer history (P = 0.12), smoking status
(P = 0.108), smoking pack-years (P = 0.342), platelet count
(P = 0.110) white blood cell (WBC) count (P = 0.253) or
the percentage of neutrophils (P = 0.144), lymphocytes
(P = 0.116) or monocytes (P = 0.473) in WBC. Further
analysis indicated that no significant correlation was
found between mtDNA content and levels of platelet or
white blood cell types (data not shown). These data suggest that levels of platelet or white blood cell types may
not have notable effect on mtDNA content in blood
samples. Among the total 414 cases, 175 patients were
diagnosed with low-grade gliomas (WHO grade I/II)
and 239 were diagnosed with high-grade gliomas (WHO
grade III/IV).
We measured mtDNA content using a real-time PCRbased method in all samples. The mean inter-assay coefficient variation (CV) of real-time PCR reaction was 6.9%
(range, 3.9% to 9.1%), whereas intra-assay CV was 4.2%
(range, 2.4% to 6.9%). We observed that mtDNA content
in PBLs was significantly higher in glioma cases than that
in controls (P < 0.001). The median values of normalized
mtDNA content were 0.99 (range, 0.02-3.89) and 0.71
(range, 0.07-2.72) in cases and controls, respectively
(Figure 1). Furthermore, we compared the mtDNA content according to host characteristics. As shown in Table 2,
the case–control difference was still significant in all stratified subgroups. No significant modulating effect of selected
characteristics on mtDNA content was found in both cases
and controls, with P value ranging from 0.101 to 0.982.
We then performed an unconditional logistic regression
analysis to evaluate the association between mtDNA content or other selected characteristics and glioma risk. When
participants were dichotomized into high and low groups
based on the median value of mtDNA content in controls
(Figure 2), we observed that high mtDNA content was significantly associated with a 4.79-fold increase in risk of glioma (95% CI, 3.49-6.59) in the univariate logistic regression
model and a 4.82-fold increase in risk of glioma (95% CI,
3.50 - 6.63) after adjusting for the confounding effects of
age, sex, smoking status and family history of cancer in the
multivariate logistic regression model. Next, participants
were categorized into three groups according to the tertile
values of mtDNA content in healthy controls (Figure 2).
When the first (lowest mtDNA content) tertile was used as
the reference group, we observed that the adjusted ORs for
the second and third tertile were 2.28 (95% CI, 1.49 - 3.50)
and 6.38 (95% CI, 4.24 - 9.36), respectively. When participants were categorized into four groups according to quartile values of mtDNA content in healthy controls, the
adjusted ORs for the second, third, and fourth quartiles
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Table 1 Distribution of selected characteristics in glioma
cases and healthy controls
Variables

Case (n = 414) Control (n = 414) P value

Age(years), No. (%)

0.491

<47

204 (49.27)

206 (49.86)

≥47

210 (50.73)

208 (50.14)

Male

241 (58.21)

241 (58.21)

Female

173 (41.79)

173 (41.79)

Sex, No. (%)

1.000

Smoking status, No. (%)

0.108

Never

318 (76.81)

329 (79.47)

Ever

96 (23.19)

85 (20.53)

Family history of
cancer, No. (%)
Yes
No

0.103
45 (10.87)

32 (7.73)

369 (89.13)

382 (92.27)

Pack-years of smokinga,
Mean (SD)

26.20 (14.94)

25.29 (13.05)

0.342

White blood cell count
(109/L), Mean (SD)

6.2 (4.17)

5.9 (3.32)

0.253

% of neutrophils, Mean
(SD)

64.7 (25.32)

62.2 (23.85)

0.144

% of lymphocytes,
Mean (SD)

28.1 (19.53)

30.3 (20.64)

0.116

% of monocytes, Mean
(SD)

5.4 (3.88)

5.6 (3.35)

0.473

Platelet count (109/L),
Mean (SD)

245 (69.05)

253 (74.51)

0.110

WHO grade
I/II

175 (42.27)

III/IV

239 (57.73)

SD, standard deviation.
a
Only for ever smokers.

were 0.90 (95% CI, 0.52 - 1.53), 3.38 (95% CI, 2.15 - 5.31),
and 5.81 (95% CI, 3.74 - 9.03), respectively.
We further used a restricted cubic spline function in
the logistic regression model to evaluate the shape of the
association between mtDNA content and glioma risk. As
shown in Figure 3, our result exhibited an S-shaped
association between them. With the increase of mtDNA
content, the glioma risk decreased before the inflection
point [log (mtDNA content) = −0.25]; whereas glioma
risk gradually increased with the increase of mtDNA
content after the inflection point. The P value of test for
nonlinearity is 0.008. Our stratified analysis showed that
higher mtDNA content was associated with increased
glioma risk in all strata (Table 3). We also analyzed the
interactive effects of mtDNA content and host characteristics on the risk of glioma. The P values for the interaction of mtDNA content with sex, age, smoking status
and family cancer history were 0.193, 0.467, 0.072 and

Figure 1 Comparison of relative mitochondrial DNA (mtDNA) copy
number between glioma cases and healthy controls. Two-sided
Mann–Whitney U test was used to evaluate difference of mtDNA copy
number between glioma cases and healthy controls. ***, P < 0.001.

0.287, respectively. These data suggest that the association
between increased glioma risk and higher mtDNA content
was not modulated by major host characteristics.

Discussion
In this case–control study, we found that glioma patients
exhibited significantly higher mtDNA content than
healthy controls. Our findings also demonstrated a typical S-shaped association between high mtDNA content
and increased glioma risk. These results suggest that
mtDNA content in PBLs might be a potential susceptibility biomarker for early preventive screening of glioma.
To date, there are only a few risk factors identified to be
associated with the risk of glioma, which only account
for a small part of glioma cases [21]. Therefore, if our
data are confirmed, novel strategy based on leukocyte
mtDNA content examination can be established and
would help to improve the screening of individuals who
would probably develop glioma.
Several previous studies reported that higher mtDNA
content in PBLs was significantly associated with an
increased risk of NHL, lung cancer, and breast cancer
[18,19,22]. These results are consistent with our present
finding, indicating for the first time a similar positive
correlation between PBL mtDNA content and glioma
risk. Moreover, significant increase in mtDNA content
has been found in both malignant glioma cell lines and
tissues, suggesting that mtDNA content alteration may
be an early molecular event in the development and progression of glioma [23-25]. Previous studies have also
yielded similar results in cancers of endometrium, head
and neck, thyroid gland [26], ovary [9], large intestine
[27,28], and lung [27], where mtDNA content was significantly higher in tumor tissues as compared with the
corresponding non-tumor adjacent tissues. However, on
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Table 2 mtDNA copy number by host characteristics of glioma cases and healthy controls
Variables

Case

Control

P value

No.

mtDNA copy number, median (range)

No.

mtDNA copy number, median (range)

Male

241

0.98 (0.12 to 3.89)

241

0.70 (0.07 to 2.72)

< 0.001

Female

173

1.01 (0.02 to 3.22)

173

0.74 (0.15 to 2.52)

< 0.001

Sex

P value

0.431

0.101

Age, years
<47

204

0.96 (0.02 to 3.89)

206

0.70 (0.13 to 2.72)

< 0.001

≥47

210

1.03 (0.03 to 3.55)

208

0.72 (0.07 to 2.52)

< 0.001

P value

0.165

0.877

Smoking status
Never

318

0.98 (0.02 to 3.61)

329

0.69 (0.07 to 2.72)

< 0.001

Ever

96

1.02 (0.03 to3.89)

85

0.71 (0.12 to 2.55)

0.001

P value

0.251

0.267

Family history of cancer
Yes

45

0.90 (0.03 to 3.26)

32

0.72 (0.18 to 2.66)

0.002

No

369

0.99 (0.02 to 3.89)

382

0.69 (0.07 to 2.72)

< 0.001

P value

0.151

0.803

WHO grade
I/II

175

0.98 (0.04 to 3.55)

III/IV

239

1.00 (0.02 to 3.89)

P value

0.982

mtDNA, mitochondrial DNA.

the contrary, previous studies have also reported negative correlations between mtDNA content and risk of
cancers such as HCC [29] and RCC [17]. Furthermore,
in comparison to paired normal tissue, a significant
decrease in mtDNA content was reported in the tumor
tissue of cancers including HCC [29], gastric carcinoma
[11], breast cancer [13,30], and RCC. Therefore, it is

most likely that the change in mtDNA content is not
simply a function of enhanced cellular proliferation in
neoplastic cells, but also has some degree of specificity for
particular cancer type. The reason for the tumor-specific
association between mtDNA content and cancer risk remains to be evaluated, although it is likely to be regulated
by various genetic, molecular, and cellular determinants.

Figure 2 Risk of glioma as estimated by selected characteristics. Odds radios (ORs) were calculated by using logistic regression analysis and the
tests were two-sided. Both groups were adjusted for age (years, continuous variable), sex, smoking status and family history of cancer where appropriate.
Squares indicate study-specific odds ratios; horizontal lines, study-specific confidence intervals (CIs); dotted vertical line, odds ratio of 1.0.
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Figure 3 Association between leukocyte mitochondrial DNA
(mtDNA) copy number and subsequent risk of glioma. mtDNA
copy number and odds ratio (OR) values were transformed to
common logarithm. There was an S-shaped relationship between
mtDNA copy number and glioma risk (P for nonlinearity = 0.009).

Further studies are needed to elucidate the molecular
mechanisms underlying the association between mtDNA
content and cancer risk.
In our study, we found that glioma cases exhibited
higher leukocyte mtDNA content than healthy controls.
However, this observational study could not tell whether
mtDNA content alterations are the cause or consequence
of tumorigenesis, which is a limitation inherent in case–
control study design. A previous study have reported that
mtDNA content appears to have high heritability (ie, proportion of phenotypic variation in a population that is

attributable to genetic variation among individuals) [17].
In addition, several prospective studies have demonstrated
that higher mtDNA content is associated with the risks of
CRC [31], NHL [19], pancreatic cancer [32] and lung cancer [18]. In addition, our data also showed that glioma
grade did not exhibit any remarkable effect on mtDNA
content. All these findings suggest that alterations of
mtDNA content may happen before cancer establishment.
Future studies including animal cancer models and large
prospective cohorts are needed to investigate the mtDNA
content alterations and its biological roles in glioma.
Considering the crucial role of oxidative stress in
tumorigenesis of glioma [25], our finding that higher
mtDNA content was associated with an increased risk of
glioma is not surprising. Elevated mtDNA content is
commonly caused by some forms of oxidative stress in
experimental models [33-35]. It has been shown that
cells under mild oxidative stress may increase biogenesis
of mitochondria and mtDNA through a pathway that
bypasses cell-cycle control [36]. During the process of
ROS-associated oxidative phosphorylation, accumulation
of mtDNA mutations may occur [37]. Furthermore,
mutated mtDNA may lead to aberrant mitochondrial
biogenesis and then confer a replicative advantage to the
cells [38]. Therefore, in our study, the case–control
difference in mtDNA content might reflect the possible
case–control difference in oxidative stress.
In the present study, we did not find any significant
association between the mtDNA content and major host
characteristics such as sex, age, smoking, and family history of cancer in both cases and controls. These observations are in line with some of the previous reports, but
inconsistent with others that showed age- or smoking-

Table 3 mtDNA copy number and glioma risk estimates by selected variables
Casesa (n)

Variables

Controlsa (n)

Adjusted ORb
(95% CI)

P value

High

Low

High

Low

Male

198

43

122

119

4.85 (3.52 to 6.71)

<0.001

Female

139

34

86

87

4.26 (2.83 to 5.94)

<0.001

<47

167

37

103

103

4.81 (3.42 to 6.69)

<0.001

≥47

170

40

105

103

4.84 (3.59 to 6.65)

<0.001

Never

275

43

166

163

4.92 (3.43 to 6.82)

<0.001

Ever

62

34

42

43

1.98 (1.14 to 3.02)

0.014

Yes

28

17

16

16

2.14 (1.19 to 3.36)

0.006

No

309

60

192

190

4.89 (3.36 to 6.84)

<0.001

Sex

Age, years

Smoking status

Family history of cancer

95% CI, 95% confidence interval; mtDNA, mitochondrial DNA; OR, odds ratio.
a
Cases and controls were dichotomized based on the median value of controls.
b
Adjusted by age, sex, smoking status, family history of cancer and histology type where appropriate.
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dependent changes in mtDNA content [39,40]. Additional larger studies with greater statistical power are
needed to provide additional insights into the effects of
interaction between mtDNA content and host variables
on the modulation of glioma risk.
This study has several strengths and limitations. Our
population is enrolled from Xi’an and its adjacent areas,
which are highly attractive for conducting populationbased research. The geographical stability with low mobility rate could greatly reduce the potential confounding
effects of the heterogeneous participant characteristics.
However, because it was not a random sample of the
general population, there was still a certain risk of selection bias if there were any difference in terms of the studied exposures. Moreover, due to inaccurate understanding
of IR exposure questionnaire by participants, IR exposure
data was not acceptably consistent when cross-check was
performed by independent interviewers. We thus were
unable to evaluate the mtDNA-IR interactions underlying
risk of gliomas. Because the frequency of IR was rather
low as reported by epidemiological studies in China [41],
studies with larger sample size are still needed for a meaningful analysis on this interaction in future. In addition,
our study cannot bypass the reverse-causation problem,
an intrinsic limitation of the case–control study design,
although previous studies have provided strong direct
evidence that mtDNA content may serve as a constitutive
genetic marker for cancer susceptibility. Therefore, future
prospective epidemiological studies are warranted to
further confirm our findings.

Conclusions
In summary, our data for the first time demonstrated
that higher mtDNA content in PBLs was significantly associated with increased glioma risk. This is an initial step
to evaluate whether the mtDNA content measured in
PBLs can be used as a biomarker for early preventive
screening of glioma. Once validated, mtDNA content
could be incorporated with other available risk factors to
construct a multivariate risk assessment model for identifying subjects with high risk of glioma.
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